Amarin Omega-3 Drug Lowers Blood-Fat Levels in TrialChris Kay
An Amarin Corp. experimental medicine lowered fatty chemicals in the blood by as much as 45 percent in a final-stage clinical study. Amarin rose in pre- market trading.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.